Trade Name(s)

  • Zavzpret

Ther. Class.

vascular headache suppressants

Pharm. Class.

calcitonin gene-related peptide receptor antagonists


Acute treatment of migraine with or without aura.


Binds to and inhibits the calcitonin gene-related peptide (CGRP) receptor, which reduces the neuroinflammatory and vasodilatory effects of CGRP.

Therapeutic Effect(s):

Reduction in pain and other bothersome symptoms associated with migraine.


Absorption: 5% absorbed following intranasal administration.

Distribution: Extensively distributed to tissues.

Protein Binding: 90%.

Metabolism and Excretion: Primarily metabolized in liver via the CYP3A4 isoenzyme, and to a lesser extent by the CYP2D6 isoenzyme. Primarily excreted as unchanged drug in feces (80%) and urine (11%).

Half-life: 6.55 hr.

TIME/ACTION PROFILE (relief of migraine pain)

IN0.5 hr2 hrup to 48 hr


Contraindicated in:

  • Hypersensitivity;
  • Severe hepatic impairment;
  • Severe renal impairment (CCr <30 mL/min).

Use Cautiously in:

  • OB:   Safety not established in pregnancy;
  • Lactation:  Safety not established in breastfeeding;
  • Pedi:   Safety and effectiveness not established in children.

Adverse Reactions/Side Effects

EENT: nasal discomfort

GI: taste disorders, nausea, vomiting

Misc: hypersensitivity reactions

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



  •  Organic anion transporting polypeptide 1B3 (OATP1B3) inhibitors  or  sodium taurocholate co-transporting polypeptide (NTCP) transporter inhibitors, including  rifampin  may ↑ levels and risk of toxicity; avoid concurrent use.
  •  Organic anion transporting polypeptide 1B3 (OATP1B3) inducers  or  sodium taurocholate co-transporting polypeptide (NTCP) transporter inducers  may ↓ levels and effectiveness; avoid concurrent use.
  •  Intranasal decongestants  may ↓ absorption of zavegepant; avoid concurrent use. If concurrent use unavoidable, administer intranasal decongestant ≥1 hr after zavegepant.


Intranasal (Adults): Single dose of 10 mg in one nostril.


Nasal spray: 10 mg/spray


  • Assess pain location, character, intensity, duration, and associated symptoms (photophobia, phonophobia, nausea, vomiting) of migraine pain.
  • Monitor frequency of migraine headaches.
  • Monitor for signs and symptoms of hypersensitivity reactions (anaphylaxis, dyspnea, rash, pruritus, urticaria, facial edema). If a hypersensitivity reaction occurs, discontinue zavegepant and begin therapy as needed.


  • Intranasal Administer a single 10 mg spray in one nostril, as needed. Do not administer more than one spray in each 24 hr period.

Patient/Family Teaching

  • Instruct patient to administer zavegepant as directed. Do not test or prime the nasal spray before use. Advise patient to read the  Patient Information  before starting therapy and with each Rx refill in case of changes.
  • Advise patient to avoid using intranasal decongestants with zavegepant; may decrease the absorption of zavegepant. If concurrent use is unavoidable, administer intranasal decongestants at least 1 hr after zavegepant administration.
  • Advise patient to notify health care professional immediately if signs or symptoms of hypersensitivity reactions (shortness of breath, rash, swelling of the face, mouth, tongue, or throat) occur.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Rep:  Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Decrease in pain and symptoms associated with migraine headaches.